ANL 11.26 Increased By ▲ 0.14 (1.26%)
ASC 10.15 Increased By ▲ 0.17 (1.7%)
ASL 11.98 Increased By ▲ 0.13 (1.1%)
AVN 71.01 Decreased By ▼ -0.23 (-0.32%)
BOP 6.01 Increased By ▲ 0.06 (1.01%)
CNERGY 5.31 Increased By ▲ 0.04 (0.76%)
FFL 7.16 Increased By ▲ 0.46 (6.87%)
FNEL 6.17 Increased By ▲ 0.07 (1.15%)
GGGL 12.00 Increased By ▲ 0.14 (1.18%)
GGL 16.10 Increased By ▲ 0.18 (1.13%)
GTECH 9.49 Increased By ▲ 0.14 (1.5%)
HUMNL 6.63 Increased By ▲ 0.07 (1.07%)
KEL 2.61 Increased By ▲ 0.03 (1.16%)
KOSM 3.09 Increased By ▲ 0.03 (0.98%)
MLCF 28.70 No Change ▼ 0.00 (0%)
PACE 2.97 Decreased By ▼ -0.02 (-0.67%)
PIBTL 6.10 Increased By ▲ 0.01 (0.16%)
PRL 15.51 Increased By ▲ 0.46 (3.06%)
PTC 7.23 Increased By ▲ 0.06 (0.84%)
SILK 1.20 Decreased By ▼ -0.04 (-3.23%)
SNGP 26.49 Increased By ▲ 0.34 (1.3%)
TELE 10.95 No Change ▼ 0.00 (0%)
TPL 9.15 Increased By ▲ 0.10 (1.1%)
TPLP 16.14 Increased By ▲ 0.22 (1.38%)
TREET 29.96 Increased By ▲ 0.06 (0.2%)
TRG 76.43 Decreased By ▼ -0.57 (-0.74%)
UNITY 22.60 Increased By ▲ 0.15 (0.67%)
WAVES 13.75 Increased By ▲ 0.80 (6.18%)
WTL 1.58 Increased By ▲ 0.03 (1.94%)
YOUW 5.05 Increased By ▲ 0.01 (0.2%)
BR100 4,294 Increased By 21.7 (0.51%)
BR30 14,969 Increased By 71.3 (0.48%)
KSE100 43,131 Increased By 147.1 (0.34%)
KSE30 16,409 Increased By 59.4 (0.36%)

KARACHI: Pfizer Pakistan and BioNTech SE Monday announced an agreement with the National Disaster Management Authority (NDMA) to supply 13 million doses of their Covid-19 vaccine - BNT162b2. Deliveries are planned during course of 2021.

“We are deeply honored to work with the Pakistan government and to marshal our scientific and manufacturing resources toward our shared goal of bringing a Covid-19 vaccine to the people of Pakistan as quickly as possible,” said Pfizer Pakistan country manager Syed Muhammad Wajeehuddin.

BioNTech chief business and chief commercial officer Sean Marett said, “I would like to thank the Pakistan government for its support and putting trust in our ability to develop a vaccine that, we believe, has the potential to help address this global pandemic threat. Our goal remains to deliver a global supply of a well-tolerated and effective COVID-19 vaccine for many people around the world, as quickly as we can.”

Pfizer and BioNTech aim to manufacture more than 3 billion doses of their Covid-19 vaccine globally in total by the end of 2021, assuming updated six-dose labeling, continuous process improvements, expansion at current facilities and contingent upon adding new suppliers and contract manufacturers.

The vaccine, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer, and the marketing authorization holder is BioNTech in the United States, Europe, UK, Canada, and other countries.—PR

Copyright Business Recorder, 2021

Comments

Comments are closed.